REFERENCES
3. Peng DT, Xu XH, Yu ZY. Determination study of neostigmine test results. Chin J Neuroimmunol Neurol 2007;14:1-3.
4. Zivkovic SA, Shipe C. Use of repetitive nerve stimulation in the evaluation of neuromuscular junction disorders. Am J Electroneurodiagnostic Technol 2005;45:248-261.
5. Cui LY, Guan YZ, Wang H, Tang XF. Single fiber electromyography in th e diagnosis of ocular myasthenia gravis: report of 90 cases. Chin Med J (Engl) 2004;117:848-51.
6. Cont-i Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006;16:2843-54.
8. Meriggioli MN, Sanders DB. Advances in the diagnosis of neuromuscular junction disorders. Am J Phys Med Rehabil 2005;84:627-38.
9. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 2006;16:459-67.
10. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004;29:484-505.
11. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW, European Federation of Neurological Societies. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;17:893-902.
13. Luchanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 2008;21:8-15.
14. Zhang W, Li ZY. Progress of ocular myasthenia gravis. Chin J Neurol 2007;40:564-6.
15. Antonio-Santos AA, Eggen berger ER. Medical treatment options for ocular myasthenia gravis. Curr Opin Ophthalmol 2008;19:468-78.
16. Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci 2007;261:127-33.
19. Parr JR, Jayawant S. C hildhood myasthenia: clinical subtypes and practical management. Dev Med Child Neurol 2007;49:629-35.